Henry McCance, chairman emeritus of Greylock Partners, co-founded Cure Alzheimer’s Fund (CAF) in 2005 after getting frustrated with the lack of knowledge about the disease when his wife was diagnosed. He was interviewed by the Boston Business Journal about his venture capital approach to funding Alzheimer's disease research.
BOSTON— Excessive levels of the protein CD33 can impede the clearance of the plaque-forming protein, amyloid beta, the key component of senile plaques in the brains of Alzheimer’s disease patients. The discovery, made by Dr. Rudolph Tanzi and colleagues at Massachusetts General Hospital, and co-funded by the Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) will be published in the journal Neuron.
Cure Alzheimer’s Fund is saddened by the terror attack at the Boston Marathon. Our hearts go out to all who have been affected by these horrible incidents. We are so proud of the runners, all those behind the scenes and all who supported our marathon running team this year. We are happy to report that none of our team was near enough to the blasts to be injured. We want to say thank you to those who supported our marathon team. Also thanks to the many of you who have expressed concern.
The study, led by Cure Alzheimer’s Research Consortium member Sam Gandy, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai, examined how elements in air pollution such as nickel nanoparticles affect the levels of certain peptides in the brain that are found to be at heightened levels in patients suffering from Alzheimer’s Disease.
“We don’t yet completely understand why the peptides accumulate, but we do know the genes responding to the peptides play an important role in developing Alzheimer’s,” said Gandy.
The President states in the budget message for the National Institutes of Health that the proposed budget delivers on the "... Administration's commitment to enhance investment in Alzheimer's research" by adding approximately $80 million to the current year’s amount. This commitment which moves Alzheimer’s research from about 1.6% of the NIH budget to about 1.8% includes, "... investments in basic research on the fundamental causes and mechanisms of disease ..."
Traumatic Brain Injury (TBI) can lead to neurodegenerative syndromes that include Alzheimer's Disease (AD) and Chronic Traumatic Encephalopathy (CTE).
The April issue of Nature Reviews Neurology is devoted to Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE). Cure Alzheimer’s Fund research consortium member, Sam Gandy, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai is senior author of the lead review and overview.
According to a new RAND study published today in the New England Journal of Medicine, dementia care costs are now comparable to those of heart disease and cancer. And unlike most chronic diseases, rates of dementia in the population are rising rapidly. The study estimates that about 3.8 million Americans currently suffer from dementia, and predicts that this number will climb to 9.1 million by 2040. The cost of the disease to the country will rise proportionally if a cure is not found.